Excerpt 1 "As previously reported, data confirm PDS0101 treatment activates HPV16-specific CD8+ T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8+ T cells are important mediators of antigen-specific immunity."
Remember IMTX held back the results from the IMA203 +CD8 part of the trial. Might be interesting results - also Opdivo + IMA 203 results ( BMS) held back.
IMTX trials sre still in an early phase, imo. TCR-T category still early as well, imo.
Not sure if IMTX will be presenting at the ASH. TScan is and is also in the TCR-T category with a very strategic approach, imo.
News 
Market Data 
Discover 
